Australian T1D National Screening Pilot
University of Sydney / Australian Type 1 Diabetes Clinical Research Network (funded by JDRF, now Breakthrough T1D)
Answers how to screen a country — but recruitment has closed.
A head-to-head Australian pilot of *how* to screen a whole country's children for type 1 diabetes, not whether to. Three general-population models were run side by side: genetic risk screening on the newborn heel-prick dried blood spot; genetic risk screening on an infant saliva sample at 6-12 months; and direct islet-autoantibody screening on a capillary dried blood spot at age 2, 6 or 10. Up to 3,000 children per model (up to 9,000 in total) across at least two states each, with screening uptake as the primary outcome. The pilot has closed to new registrations; its findings are meant to make the case for a government-funded national programme, which does not exist yet.
The scorecard
Deliberately heterogeneous, because comparing the models is the point: two of the three arms screen genetic risk, which stratifies who is more likely to develop autoantibodies rather than identifying who has T1D, and only the third measures islet autoantibodies directly. The genetic arms add autoantibody testing later (from about 10-11 months) to convert risk into an actual diagnosis of early-stage T1D.[1]
Children who screen positive can enter monitoring and education, the route that prevents ketoacidosis at diagnosis — but the pilot's own primary outcome is screening uptake, with feasibility, acceptability and cost-effectiveness alongside it. It was designed to change policy, not to demonstrate a clinical endpoint, and its results were not yet published at the time of this review.[1]
Explicitly general-population rather than relatives-only, across at least two states per cohort — squarely aimed at the fact that most children who develop T1D have no family history, and the gap Australia's existing relatives-focused programme cannot close.[1]
Two of the three models add nothing invasive: they reuse the newborn heel-prick blood spot already taken at birth, or a saliva sample from an infant. The third is a capillary finger-prick dried blood spot. Only screen-positive children need further testing.[1]
Recruitment has closed. This was a time-limited pilot designed to produce evidence for a national programme; there is no open, funded general-population T1D screening service in Australia today, so a family cannot act on this record — only on what it may eventually unlock.[2]
The full picture
The Australian Type 1 Diabetes National Screening Pilot asked a question most screening programmes skip: not whether to screen children for type 1 diabetes (T1D), but how. Led from the University of Sydney through the Australian Type 1 Diabetes Clinical Research Network and funded by JDRF (now Breakthrough T1D), it ran three different general-population screening models against each other in the same country at the same time, so that a future national programme could be built on evidence rather than preference.12
The three models
Every model is aimed at the general population — any child, no family history required — because most people who develop T1D have no relative with it.1
- Newborn genetic screening. A genetic risk score is calculated from the dried blood spot already collected at the newborn heel prick, so no extra sample is taken. Children at higher genetic risk are then offered islet-autoantibody testing from around 11 months of age.1
- Infant saliva genetic screening. A genetic risk score from a saliva sample collected at 6-12 months, with autoantibody testing from around 10 months for those at higher risk.1
- Direct autoantibody screening. A capillary dried blood spot at age 2, 6 or 10, measuring islet autoantibodies straight away — no genetic step.1
The distinction matters. A genetic risk score says a child is more likely to develop the autoimmunity that leads to T1D; islet autoantibodies say the autoimmune process has actually begun. Two or more autoantibodies is what defines presymptomatic (stage 1 or stage 2) T1D. The genetic arms are therefore a funnel, narrowing who gets antibody-tested and when, while the third arm skips the funnel and tests directly.
Size and what it measured
The pilot aimed to enrol up to 3,000 children per model — up to about 9,000 in total — in at least two Australian states per cohort. Its primary outcome was screening uptake: what proportion of families offered each model actually took it up. Feasibility, acceptability and cost-effectiveness sit alongside it.1 That is a policy question dressed as a study, and it is the honest reason this record scores modestly on actionability: the pilot was built to tell a government which screening model a country would actually use, not to prove that screening changes an individual child's outcome. That case is already made elsewhere — general-population programmes such as Germany's Fr1da and the UK's ELSA are the evidence that finding T1D early collapses the rate of diabetic ketoacidosis (DKA) at diagnosis.
Where it stands now
The protocol describes a pilot period of July 2022 to June 2024, and the study's own website states that it has closed for new self-registrations.13 So this is not something a family can join today. As of this review we found no published results.
That leaves Australia in a familiar position: a strong evidence-gathering exercise has finished, and the programme it was designed to justify does not exist. The screening an Australian family can actually access right now is Type1Screen, the free national programme — but it is offered to people with a family history of T1D, which by design misses the majority of future cases. Closing that gap is precisely what this pilot was for.
How to read this record
We list the pilot as pipeline, not available, deliberately. What is pending is not a product but a decision: whether Australia funds general-population screening, and on which of the three models. Treat the pilot as the evidence being assembled for that decision, and watch for its published findings.
References
-
Bell KJ, et al. Protocol for the Australian Type 1 Diabetes National Screening Pilot: Assessing the feasibility and acceptability of three general population screening models in children. Diabetic Medicine 41(11):e15419 (2024). https://pubmed.ncbi.nlm.nih.gov/39129150/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7
-
Breakthrough T1D. Australian Type 1 Diabetes National Screening Pilot: advancing the evidence base towards national public health implementation (grant record). https://www.breakthrought1d.org/grants/australia/nsw/australian-type-1-diabetes-national-screening-pilot-advancing-the-evidence-base-towards-national-public-health-implementation/ ↩
-
Type 1 Diabetes National Screening Pilot (official study site). kidsdiabetesscreen.com.au (accessed 2026). https://www.kidsdiabetesscreen.com.au/ ↩
Coming soon
ETA · Findings are intended to support the case for a government-funded national general-population screening programme. No such programme has been announced, and no public timeline for a decision exists.
- →Pilot findings — screening uptake, feasibility, acceptability and cost-effectiveness of the three models — intended to inform the case for a government-funded national screening programme in Australia
Sources
- [1]Protocol for the Australian Type 1 Diabetes National Screening Pilot: Assessing the feasibility and acceptability of three general population screening models in children · peer-reviewed · 2024-08-01 — Bell KJ et al., Diabetic Medicine 41(11):e15419. Sets out the three screening models, up to 3,000 children per cohort across at least two states each, screening uptake as the primary outcome, and a pilot period of July 2022 to June 2024.
- [2]Type 1 Diabetes National Screening Pilot (official study site) · registry — States that the pilot has closed for new self-registrations.
- [3]Australian Type 1 Diabetes National Screening Pilot: advancing the evidence base towards national public health implementation · manufacturer — Funder's grant record. We do not publish a funding figure here because we could not verify one against a primary source.